Guangzhou Wanfu Biotechnology Co., Ltd. officially opened on 1992 with a registered capital of about 343 million yuan. Under the background of strong government support, it has developed into a national high-tech enterprise integrating R&D, in-vitro diagnosis and rapid detection products production and sales. In addition, it also belongs to the industry pioneer of POCT in China.

In terms of independent research and development, the company also has related practices, and has always insisted on investment and constantly increased efforts to ensure product innovation, which requires such high-intensity R&D investment, and in terms of business, it has also strengthened its efforts to extend outward. At present, the company has set up R&D bases in Guangzhou, Shenzhen and San Diego, USA. In terms of R&D personnel, there are 532 people, including not only professionals in biochemistry and clinical medicine, but also professionals in microelectronics technology. R&D investment intensity and R&D team strength are in the leading position in the industry.

In the major consumption areas of POCT in the world, there are many developed European countries and regions, such as the United States, and the market supervision is also very strict. The requirement for entering the above-mentioned market is high product quality, and it takes a long time to apply for market access qualification. In 2004, the company gradually began to explore overseas markets. Up to now, its products have been sold in 1 10 countries and regions, which constitutes a first-Mover advantage strategy. Through the long-term exploration of overseas markets, the company's product research and development ideas are clear and mature, and the enterprise management level, quality management system and market analysis ability have also been greatly improved.

The proportion of POCT products in the global IVD market is quite high, accounting for 29%. In the IVD market in China, POCT only accounts for 1 1%, which shows that POCT has great development space in China. Wanfu Bio owns the only national engineering laboratory in the POCT field, which is expected to fully benefit from the development of the POCT market, and by going up one flight of stairs in the future.